Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
February 24, 2022
Earnings Call Speaker Segments
Holly Manning
executiveThanks, operator. Hello, everybody, and good morning. It's great to have you join Agios' conference call for the fourth quarter of 2021. Slides for today's call can be found in the Investors area of our site, agios.com. Joining me today, and offering prepared comments, are our Chief Executive Officer, Dr. Jackie Fouse; Dr. Sarah Gheuens, who serves as Chief Medical Officer; our Chief Commercial Officer, Richa Poddar; Jonathan Biller, our Chief Financial Officer and Head of Corporate Affairs; and our Chief Scientific Officer, Dr. Bruce Car, who'll be here for Q&A. Ahead of beginning, please let me remind you that certain remarks made during this call will contain forward-looking statements. A range of risks, uncertainties and other factors — among them those described in our latest SEC filings, plus any subsequent submissions we might file with the SEC — could cause real events and results to differ materially from what any forward-looking statements express or imply. So with that, I'll hand things over to Jackie.
Jacqualyn Fouse
executiveThanks, Holly. Morning, everyone, and thank you for being on the call for our results covering the fourth quarter of 2021. When I think back on 2021, my mind goes to the same point last year, when we had only just shared that we would be divesting the oncology business, and we were deep in the work of building a strategy for Agios's next phase, one centered exclusively on genetically defined diseases. Now, 12 months afterward, I'm amazed by what all of us have managed to achieve alongside our teams throughout every part of the business, and I feel enormously positive about the future we're constructing; right after the FDA cleared PYRUKYND last week, our commercial group has hit the ground running, talking with physicians and teaching them about PK deficiency. Richa, here with us on her first earnings call since becoming Chief Commercial Officer, will share more detail on how we're launching commercially. Our clinical group is charging ahead, enrolling our pivotal studies in thalassemia and sickle cell disease, while simultaneously handling start-up work for our pivotal pediatric PK deficiency trials, the sickle cell disease cohort of the AG-946 Phase I effort, and the AG-946 MDS study. As ever, our research organization keeps its attention on the coming wave of discovery and preclinical programs, the ones we presented at our Investor Day last November. Crucially, since selling off the oncology business gave us considerable cash and a robust balance sheet backing our near- and long-term business strategy, we're able to stay focused on delivering against our business priorities at a moment when financial markets are volatile and uncertain. During the past year, we cut our share count by over 23% via our share repurchase program, all while keeping financial flexibility to speed up pipeline programs and potentially seek out complementary business development opportunities should they emerge. Looking toward this year, we're dedicated to sustaining our record of strong execution in research, clinical and commercial. With that, I'll hand things over to Sarah.
Sarah Gheuens
executiveThank you, Jackie. Over the past year, the output of our clinical group has genuinely been extraordinary: we finished 2 pivotal studies, kicked off 3 additional ones, moved a novel compound into its initial human trial, started launch preparations for many other studies that will begin during this year, and filed 2 regulatory submissions. Let me begin with pyruvate kinase deficiency, where we take pride in being the first organization to develop a therapy for this lifelong hemolytic anemia. The FDA granted approval last week to PYRUKYND for treating hemolytic anemia in adults who have PK deficiency. That label, which we went through thoroughly during our approval investor webcast, covers every genotype and all transfusion statuses. Although this marks a major achievement for everyone here at Agios, we recognize that our efforts in PK deficiency are nowhere near finished. Our marketing authorization application for adult PK deficiency is currently being reviewed in the EU, and we are still on schedule for a decision from the EMA during the second half of 2022. Furthermore, our team is busy carrying out start-up work for 2 pivotal trials involving pediatric patients with PK deficiency — both those who are not regularly transfused and those who are regularly transfused. We anticipate that ACTIVATE-kids and ACTIVATE-kidsT will begin in mid-2022. One of our central priorities is to keep clarifying the burden of PK deficiency and to understand how PYRUKYND affects patients over the long term. At ASH in December, we were delighted to present new data demonstrating that patients in the extension studies maintained their response, along with PYRUKYND's capacity to lower iron overload and enhance ineffective erythropoiesis. Both our adult PK deficiency extension studies and the PEAK Registry continue, and we anticipate providing further findings from these trials at upcoming medical meetings. Past PK deficiency, we think PK activation could serve a meaningful function in treating thalassemia and sickle cell disease. Late last year, we launched our 2 worldwide placebo-controlled pivotal trials of PYRUKYND in thalassemia — ENERGIZE and ENERGIZE-T — plus the Phase II segment of our Phase II/III study in sickle cell disease, RISE UP. Dosing has begun for the first patients across all 3 trials, and our team is concentrating on sustained global site activation and patient enrollment work. We aim to finish enrollment in the Phase II portion of RISE UP and to enroll a substantial share of patients in ENERGIZE and ENERGIZE-T before the year ends. At ASH, we provided important new data across both disease areas. In particular, we delivered the first extension data backing long-term PYRUKYND use in both alpha and beta nontransfusion-dependent thalassemia. Also, our NIH collaborators presented a full data set from the core period of their Phase I study, while our collaborators in the Netherlands presented the initial analysis from their investigator-sponsored trial, which included data on point of sickling. Taken as a whole, this body of evidence keeps showing that PYRUKYND could have a real effect on these hemolytic anemia. Building on our trailblazing knowledge of PK activation, we are also moving forward with AG-946, our new PK activator. Right now AG-946 is under assessment in a Phase I trial that includes a healthy volunteer portion and, after that, a sickle cell disease portion. We are still enrolling healthy volunteer multiple ascending dose cohorts, and we expect to launch the sickle cell disease cohort during the first half of this year. During our IR Day in November, we laid out our intentions to study AG-946 in anemia tied to low to intermediate risk to MDS. That Phase IIa trial should begin before this year is over. At this point I'll hand the call over to Richa, who serves as our Chief Commercial Officer.
Richa Poddar
executiveThanks, Sarah. This is a thrilling moment for the commercial side of the business, since we're rolling out our very first medicine for a disease with a genetic cause; over the past seven days, our reps in the field have been busy talking with doctors and providing education about the first approved drug for pyruvate kinase deficiency. As we described during our approval investor event, the way we're taking this to market centers on educating people about the disease, building understanding of what PYRUKYND can offer patients who qualify, and making sure those who are eligible, who have coverage, are able to remain on the drug. Our estimate is that roughly 1,500 to 4,000 individuals in the United States are living with PK deficiency, and our educational work ahead of launch has concentrated on getting the diagnosis of PK deficiency right. That said, since it's underdiagnosed, our grasp of how prevalent it truly is should improve as the launch progresses. The availability of a therapy gives doctors a strong incentive to think about PK deficiency while evaluating patients. Among these patients, our belief is that around 30% have a diagnosis today and 80% are adults. After someone receives a PK deficiency diagnosis, they can enroll in the myAgios patient support service, which offers disease education and assistance. Any person living with pyruvate kinase deficiency may use this service, no matter what treatment they're on. If a patient has a PYRUKYND prescription, myAgios additionally collaborates with that person and their provider to secure access, deliver education about the drug, and encourage adherence over the long term. A few points deserve emphasis. For patients who qualify and have commercial or private insurance, the program brings the co-pay, coinsurance, and deductible down to $0. A single specialty pharmacy handles the prescription so that patients get a smooth experience. Right away, patients get connected with a myAgios patient support manager, who is there to assist with insurance questions and supply adherence resources so that starting PYRUKYND goes smoothly. For patients who qualify and lack insurance or are underinsured, we'll provide a Bridge and Patient Assistance Program, PAP. As we've mentioned previously, reaching optimal coverage will take roughly 12 months, and the timing can vary by insurance provider. The bulk of the expected patient mix will be commercial patients, and we expect that group to reach optimal coverage most quickly, with Medicare and Medicaid trailing; this matches what we've seen with comparable rare disease products in our research. Before formulary coverage is in place, patients must go through the medical exceptions process to get PYRUKYND, which usually takes around 6 to 12 weeks. With these factors in play, we expect revenues to be limited during the first few quarters. Beyond payer dynamics, we're also mindful of how current pandemic conditions affect our team's capacity to meet with physicians and how comfortable patients feel about seeking medical care right now. Naturally, doctors are putting direct patient care and the most acute situations first, and our team has built a thoughtful cadence for interactions with that in mind. The key point is that because our team has already been working together for several quarters now, we've built connections and set up meetings with doctors who handle PK deficiency, which means we're ready to move quickly following the approval. On top of that, we're reaching out to patients via social platforms, webinars for patients, and by working closely with advocacy groups—both to spread the word about PYRUKYND's approval and to offer assistance with managing the condition. The important thing is that our commercial approach, what we know, and the ties we've established position us well to succeed as we keep broadening PYRUKYND's use into additional genetically defined diseases; with that said, I'll hand things over to Jonathan now so he can go through the fourth quarter financials.
Jonathan Biller
executiveAppreciate that, Richa. The financial results for both the full year and the fourth quarter of 2021 are available in the press release that went out this morning, and I'll walk through the highlights. Additional specifics will be part of the 10-K we file later today. Just to note, when we discuss the fourth quarter financial results, we're comparing only our continuing operations, so the divested oncology business results are not included. Now on to operating expenses. For the fourth quarter, R&D expenses came to $73.3 million, and for full year 2021 they totaled $257 million — that's an increase of $36.2 million versus full year 2020. The main drivers of this year-over-year rise in R&D were: start-up costs tied to the PYRUKYND pivotal studies, such as ENERGIZE, ENERGIZE-T and RISE UP, which were partly offset by the closing out of the ACTIVATE and ACTIVATE-T studies, along with FDA and EMA regulatory filings and higher workforce spend throughout all of R&D. Selling, general and administrative expenses totaled $31.5 million for the fourth quarter and $121.4 million for the full year 2021; that reflects a $6.3 million increase compared with full year 2020, mainly from PYRUKYND launch preparation and disease education, which includes building out field sales, training and marketing. In addition, we recorded TIBSOVO royalty income of $2.6 million in the fourth quarter and $6.6 million for the full year 2021, which appears within the gain on sale of oncology business line item on our income statement. We closed the quarter with cash, cash equivalents and marketable securities of roughly $1.3 billion. Given this cash position, we believe we can carry out our current operating plan through major catalysts and into cash flow positivity without having to raise additional equity. With that, operator, please open the line for questions.
Marc Frahm
analystPerhaps to kick things off with Richa and the launch. I get that during the first quarter or 2, things won't be — from a sales standpoint, not particularly significant. But which launch metrics will you actually be watching to determine if this launch is going well? And I suppose, above all, for the people listening here, which of those metrics are you planning to kind of share with us?
Richa Poddar
executiveMarc, the way to look at this is through the 3 pillars we've discussed regarding what matters for a successful launch, which comes from the patient and provider journey. That covers things such as making sure diagnosis is accurate, securing inclusions for eligible patients on PYRUKYND, and then making sure they can get access and remain on therapy; so keeping that in mind, how we're approaching the launch metrics and what we believe will be most helpful is demonstrating how the disease similarity is getting better since this disease is severely underdiagnosed. How patients are being placed on treatment as reflected in PYRUKYND net sales. And then regarding formulary coverage and its progress, that's basically our plan for tracking it; so we're very aligned with how we built the strategy so that you can observe how the launch is advancing across the coming few quarters.
Marc Frahm
analystAll right, that's useful. And given that, as you mentioned in your remarks, COVID is affecting patients' visits to clinics and similar things, where would you say we stand now regarding how often the standard peak or previously diagnosed PKD patient visits a clinic where mitapivat could now be offered to them? And where do you figure that will head as, hopefully, COVID's effects lessen?
Richa Poddar
executiveYeah, it varies a great deal, Marc. Over the last year and beyond, when we researched the disease and spoke with patients, caregivers, and providers, we found that symptoms of the disease can show up at different times. So we've observed anything from a patient seeing the doctor once a year to seeing the doctor more often, with more regular transfusions; as for when they'll visit the doctor, I believe at present, since there is an approved therapy, our top priority is ensuring that the greatest number of physicians, along with a wider patient base within our community, knows the drug is available, so that patients who already have a diagnosis are walking into their doctor's office and discussing whether they qualify for PYRUKYND. That's the priority now, and it will stay the priority through the coming quarters. We've therefore adopted a very holistic strategy to make that happen; not only via face-to-face interactions, but we also have printed materials ready and people already out there having those discussions, plus we're leveraging a highly robust social media and digital effort to build buzz in the community, boosting awareness about the disease and about the product's availability.
Anupam Rama
analystCongratulations once more on the approval that came through last week. I have a quick question here. What do you expect to gain from the sickle cell disease arm of the Phase I 946 trial, considering that the real emphasis, as I understand it, sits on low intermediate MDS Phase II, which is meant to kick off later this year?
Sarah Gheuens
executiveYes, Sarah here. As for the sickle cell disease portion, clearly we are watching for any signal within sickle cell disease, though it also has relevance for hemolytic anemia more broadly. That should hand us considerable optionality when it comes to choosing our next steps, informed by the Phase I part of that study in that setting. And yes, naturally, we are quite enthusiastic about the MDS program; that is what makes that Phase I so attractive, since the healthy volunteer study within the sickle cell disease component lets us advance into MDS, and it provides a great deal of optionality in that respect.
Kennen MacKay
analystLet me add my congratulations on PYRUKYND getting approved. When we consider moving into sickle cell, could you give us some guidance on what to watch for during that Phase II segment of the RISE UP study, and what it might tell us?
Sarah Gheuens
executiveOf course. There are 2 primary endpoints in the RISE UP study — one centers on hemoglobin response, while the other examines a decrease in vaso-occlusive crisis through sickle cell pain crises. The aim here is naturally to deliver a treatment capable of addressing 2 elements that matter greatly in this condition: the hemolytic anemia piece as well as the vaso-occlusive piece. Additional insight into how patients feel and function comes from the secondary endpoints; the design of this trial therefore offers us considerable optionality through those various endpoints. And clearly, once RISE UP results come in, our hope is to offer a meaningful therapy for sickle cell disease.
Jacqualyn Fouse
executiveSarah, I believe there's something else Kennen was hoping to find out, and that's the specific things we're looking to get from the Phase II part of RISE UP that would then line up with Phase III.
Sarah Gheuens
executiveAbsolutely, of course. Regarding the Phase II in particular, what we're evaluating is safety along with efficacy, with efficacy assessed through a hemoglobin endpoint. Within that Phase II, 2 doses plus placebo were examined, which means we can choose the dose that will advance into Phase III.
Alethia Young
analystCongratulations once more on getting PYRUKYND approved. My question, I suppose, is a bit of this: when you look back at oncology and the divestiture, could you describe how you're currently approaching business development? What sorts of opportunities are you seeing, and what do you believe you may or may not have to do in order to bring new things into the pipeline? And how are you thinking about broadening that out? Obviously you held the R&D Day internally, I realize, but more concretely — externally, I mean?
Jacqualyn Fouse
executiveAlethia, this is Jackie. I'll begin, and then other folks might want to chime in. One of the first points I'd make is that because of how far we've come with the programs we run internally, along with how our understanding of cellular metabolism biology keeps evolving, our picture is clearer now than ever. And with innovation elsewhere outside of Agios having moved ahead, we can see more when it comes to how targets or mechanisms might complement each other, or ways we could push some of our biological insights forward; that's one point. Up until now, we've at least seemed — and probably genuinely felt — that Agios's strongest area for business development lies in preclinical assets or assets in early clinical stages, simply because of our scientific know-how and that of our clinical development group, translational medicine, everything along those lines. So that's generally the stage we'd likely focus on most, though we wouldn't rule out later-stage opportunities; still, that's where we probably contribute the greatest value. Looking at therapeutic category, it's fairly evident that non-malignant hematology — or classical hematology, as we refer to it — would definitely sit within our strongest area, along with other inborn errors of metabolism diseases, and I believe we've gained even greater knowledge over these past few years through our research and discovery team too. Financially speaking, deals of that kind, which we believe fall within our strongest area, could be handled comfortably using the resources at our disposal, and we're pursuing a few possibilities; with luck, we'll be able to discuss some of that eventually, but we're very eager to grow our pipeline through complementary targets or mechanisms and potentially through partnerships with other companies in various forms, research partnerships included.
Greg Harrison
analystTwo brief questions regarding the launch. To start, what responses have you received so far from payers regarding the price you made public last week? Then, based on your research, how enthusiastic are physicians about placing eligible patients on PYRUKYND? We're simply attempting to understand the kind of path we might see once we launch it completely.
Richa Poddar
executiveSure. A few points. We've held discussions both before launch and following approval, and they've been extremely favorable. We arrived at the price, I should note, while possessing a strong grasp of the condition, the way it was valued given the unmet need, and subsequently how they assess the clinical data within the disease context; thus we conducted all those discussions prior to approval so the price we set closely mirrored the input we'd gotten from every source. We've therefore adopted a thoroughly integrated method regarding price. We factored in our broader pricing and asset strategy, allowing us to maximize access for patients eligible for therapy while also making sure we keep investing in innovation. Given that, the response has been rather favorable; thus we don't expect major resistance. One point deserving mention, which we've addressed previously, is that we possessed — we have an extremely wide label, which pleases us greatly; a wider label is invariably preferable. However, we omitted the double non-missense patients, roughly 9% to 15%, plus those patients who have a hemoglobin level above 10 grams per deciliter; and since neither of these groups was part of a pivotal registration trial, certain payers might limit use among that specific population, even though the label permits use across the widest feasible population, adults with PK deficiencies. So those discussions are highly payer specific, yet they've been quite favorable. Regarding doctors, I'd say the response is overwhelmingly favorable once more, across both pre- and post-launch talks, as there had been no treatment choices. Pyruvate kinase deficiency's first case was identified in 1961; and every available therapy has largely been supportive. So you're essentially attempting to manage symptoms. This is the first and only approved therapy that genuinely addresses the root cause of the chronic hemolysis seen in this condition. Our expectation is that they'll use it in trial form for nearly all of these individuals, and certain dynamics enter the picture in connection with peer reauthorization, which we anticipate happening somewhere within a 3- to 6-month window, yet we anticipate that doctors will give it a try for nearly all of those who qualify, meaning adults who have pyruvate kinase deficiency.
Mark Breidenbach
analystGiven that 2022 really seems set to be a period focused on accruing patients in the ENERGIZE and RISE UP trials, I simply wanted to verify that we aren't missing any clinical catalysts on the horizon. So, is it fair to expect fresh clinical data from AG-946, or perhaps from the academic-sponsored mitapivat studies, during this year? My second question concerns looking ahead toward a possible EU launch for PYRUKYND. Would you contemplate bringing in a commercial partner in Europe, or forming partnerships across Europe? Also, do you have any insight into how PKD patients are spread throughout the EU — are there particular territories where patients cluster, or are they pretty widely dispersed?
Sarah Gheuens
executiveI'll handle the first question. This is Sarah speaking, and afterward I'll pass things to Richa for the second one. Regarding the data catalyst — you're correct that our attention right now is heavily on executing ENERGIZE and RISE UP. Even so, we'll keep sharing updates on the long-term extension data we're still collecting for both pyruvate kinase deficiency and thalassemia at future medical conferences. That matters a great deal, since it demonstrates how responses are maintained as time goes on. It also lets us examine other signals that need more time before they show up, like the iron overload data we recently reported at ASH. So we'll keep communicating on items such as those. Still, you're right that this is a major year for us when it comes to execution, and we're very enthusiastic about it. So yes, there's more to come.
Richa Poddar
executiveAnd then to address your Europe question — go ahead.
Mark Breidenbach
analystNo, go right ahead.
Richa Poddar
executiveYes. Let me take on your question about Europe. Regarding timing, we submitted our filing in June of last year. So we expect approval near the end of this year, and given how the pricing and reimbursement landscape functions in Europe, roughly 12 to 18 months will be needed before everything there gets resolved. We remain dedicated to patient access and to making sure patients who require our therapy can obtain it. So we're weighing every option for how best to accomplish that beyond the U.S., and we keep up that commercial infrastructure build-out. Going it alone outside the U.S. isn't the ideal path, so we're seeking partners. That might mean one partner or several partners, as you mentioned, but we have a bit of time to make some of those calls as circumstances develop. Then regarding the patient population, it's very much like the U.S., in that we don't truly observe clusters as such. It's the < >. Certain centers of excellence exist where, for the most part, patients aren't gathered in any single region.
Matt Dellatorre
analystThis is Matt, filling in for Salveen. Would you be able to go into a bit more detail regarding how we should think about pricing for PYRUKYND as well as for sickle cell, and then also say more about which patients would qualify if just a single primary endpoint gets met?
Richa Poddar
executiveAll right. As Sarah mentioned earlier, within the sickle cell program we have 2 primary endpoints. The first is hemoglobin, and the second is the annualized rate of vaso-occlusive crisis, correct? So that makes 2 primary endpoints. Our view is that should we achieve both of those primary endpoints, that would give us a highly compelling and competitively differentiated profile, since the treatments available today let you tackle only 1 of the 2 primary challenges posed by the disease. That means we have plenty of options when the data comes in and when we consider how pricing would relate to it. So for us, sickle cell represents optionality. We need to wait and see what the data shows. What the data shows will shape how we approach pricing in general. For sickle cell pricing, we'll follow a very similar path to the one we took with PKD, which is a highly holistic path; we'll engage the broader communities, examine the data, present that data to them, observe how they assess it within the context of the disease, and then reach some decisions. Should you hit only one primary endpoint, hemoglobin, say, we might look at keeping the price we already have for PKD and thal and then pursue a salvage patient population; yet even so, because of the size of the patient population and the overall value creation, our view is it would still be positive overall, even if a price cut had to be taken across all 3 indications; and with the full data package in hand, we then have yet another — we have a separate option for thinking about how we'd like to approach price. But on the whole, sickle cell, plenty of optionality, we have to wait and see what the data suggests and then take a holistic path toward figuring out the best pricing approach.
Jacqualyn Fouse
executiveAbsolutely. What I really want to do here is make this crystal clear. If you're launching a product that could end up with several indications down the road through label expansions, the smartest path is to begin with the least common condition and then work through those possible expansions one by one, since that approach leaves you with greater room to maneuver on pricing as time goes on. That's why we feel entirely at ease with our position in PKD, and with how, given the full body of clinical evidence for each indication as it emerges, we'd handle pricing over time — so we have considerable flexibility on that front.
Danielle Brill
analystMadison here, filling in for Danielle. I was simply curious whether the drug has been prescribed to any patients yet. Right. I think during last week's call, you mentioned that distribution would likely need roughly 2 weeks to fully roll out. So are you noticing any updates on that front?
Richa Poddar
executiveYes. We've been in discussions with various parties. Just to remind everyone, approval came through on Thursday, correct? So it's still early days, though we've had plenty of encouraging conversations with payers and physicians. You're correct that the drug will reach the channel in 2 weeks — inside 2 weeks, though that alone doesn't really change how physicians prescribe, but when it comes to payer dynamics, reimbursement will require about 6 to 12 weeks initially until the drugs secures a spot on formulary. There's a lot of favorable momentum, physicians are enthusiastic and so are patients, about having this treatment option on hand.
John Newman
analystI wanted to ask about how PYRUKYND is dosed upward gradually. Naturally, none of this is novel to us. You've established the dosing profile well in your pivotal trials. I'm just wondering whether you believe that gradual dose increase could impact uptake. Or is it simply that, given how severe this disease is, the absence of treatments out there, and what physicians have experienced, it likely won't matter much?
Sarah Gheuens
executiveIt's Sarah here. So precisely that final portion you brought up is what worried us, correct? So in our clinical trial program, we haven't observed any difficulties or problems related to this gradual dose increase. And truly, hematologists are quite accustomed to drugs requiring stepwise dose adjustments done through various approaches. So in fact, this is a fairly uncomplicated schedule for titrating the dose; so no concerns have reached us.
Jacqualyn Fouse
executiveMuch appreciated. Thanks to our operator as well. I want to express gratitude to each of you for the excellent questions we received today. In keeping with my usual practice, I'll close by expressing appreciation to my Agios teammates for the commitment and enthusiasm they bring to improving patients' lives; the approval of PYRUKYND and PKD has us incredibly thrilled. My thanks go out as well to every patient, caregiver, and physician who works alongside us in countless ways, above all those enrolled in our clinical trials spanning every indication. None of this would be possible, and we would not be standing here, absent patients, caregivers, and physicians. Our ties throughout...
Operator
operatorMy apologies — it seems Jackie has dropped off the line at this point. We appreciate all of you being with us today. That brings today's conference call to a close. Have a great day, everybody. You're welcome to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.